PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2026

  • ID: 4413659
  • Report
  • Region: Global
  • 377 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Eli Lilly
  • Intarcia Therapeutics
  • Merck & Co.
  • Novo Nordisk
  • Roche
  • MORE
PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2026

Summary

Type 2 diabetes (T2D) is a chronic disease characterized by insulin resistance and pancreatic ß-cell failure, with an underlying genetic predisposition heavily influenced by diet and lifestyle (Stumvoll et al., 2010). It is well recognized that many of the current therapies for T2D are generally unable to alter its natural course, with glycemic control typically deteriorating over time. This often results in increasingly complicated treatment regimens (Inzucchi et al., 2012). In the US, T2D is the leading cause of blindness, kidney failure, non-traumatic lower-limb amputations, cardiovascular disease (CVD), and mortality (Sarwar et al., 2010). It is a major cause of heart disease and stroke and is the seventh-leading cause of death among US adults.

Global Type 2 Diabetes (T2D) pharmaceutical market in the base year 2016 was $28.6B, including both branded and generic drugs. Branded products alone accounted for $23.8B across the 7MM. At 71% of the overall T2D market, the US is clearly the dominant market, totaling $20.3B in branded and generic pharmaceutical sales. This is due to the much higher prices of pharmaceuticals in this country and due to the highly diagnosed prevalence of T2D.

Over the forecast period of 2016-2026, the global T2D market will double, reaching $64.0B at a Compound Annual Growth Rate (CAGR) of 8.4%. The US will continue to grow in size most rapidly due to a dramatic increase in T2D prevalence and diagnosis, which is attributed to increased life expectancy and lifestyle changes. The US will increase its global market share from 71% to 74%, stealing market share predominantly from Japan, which will account for 9% of the overall T2D market in 2026. Sales in the US will grow by approximately 8.9% per year over the forecast period.

The report "PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2026" focuses on the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), also referred to as the “global market”.

This report provides the following information in-depth:
  • Overview of T2D, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized T2D therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2016 and forecast for ten years to 2026.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the T2D therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global T2D therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Companies mentioned in this report: Adocia, Astellas Pharma, AstraZeneca, Biocon, Boehringer Ingelheim, Bristol-Myers Squibb, Chong Kun Dang, Chugai Pharmaceuticals, Daiichi Sankyo, Diasome, Eli Lilly, GlaxoSmithKline, Intarcia Therapeutics, Ionis Pharmaceuticals, Johnson

Scope
  • Overview of T2D, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized T2D therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2016 and forecast for ten years to 2026.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the T2D therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global T2D therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy

The report will enable you to:
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global T2D therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global T2D therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global T2D therapeutics market from 2016-2026.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Eli Lilly
  • Intarcia Therapeutics
  • Merck & Co.
  • Novo Nordisk
  • Roche
  • MORE
1 Table of Contents

2 Type 2 Diabetes (T2D): Executive Summary
2.1 T2D Sales to Double Across 7MM
2.2 Multiple Opportunities Exist to Address Existing T2D Market Unmet Needs
2.3 The Arrival of Insulin Biosimilars and Abundance of “Me-Too” Drugs Illustrates Corporate Shift in Focus from Therapeutic Value Towards Competitive Pricing and Non-novel Agents that Confer Incremental Benefits
2.4 Glucagon-Like Peptide -1 Receptor Agonist Class Faces Intense Internal Competition, Largely Revolving Around Drugs’ Ability to Improve Patient Compliance/Ease of Administration and Cardiovascular Effects
2.5 Newest T2D Drug Class, Sodium-Glucose Cotransporter Inhibitors, Will Continue To Gain Significant Market Share Despite Concerns
2.6 What Do Physicians Think?

3 Introduction
3.1 Catalyst
3.2 Related Reports

4 Disease Overview
4.1 Etiology
4.2 Pathophysiology
4.3 Symptoms
4.4 Prognosis
4.5 Quality of Life

5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources Used
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for T2D in the 8MM (2016-2026)
5.5.1 Diagnosed Prevalent Cases of T2D
5.5.2 Age-Specific Diagnosed Prevalent Cases of T2D
5.5.3 Sex-Specific Diagnosed Prevalent Cases of T2D
5.5.4 Comorbidities Among the Diagnosed Prevalent Cases of T2D
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of Analysis
5.6.3 Strengths of Analysis

6 Disease Management
6.1 Diagnosis and Treatment Overview
6.1.1 Diagnosis and Referrals
6.1.2 Treatment Guidelines and Leading Prescribed Drugs
6.1.3 Clinical Practice
6.2 US
6.3 France
6.4 Germany
6.5 Italy
6.6 Spain
6.7 UK
6.8 Japan

7 Competitive Assessment
7.1 Overview
7.2 Strategic Competitor Assessment
7.3 Product Profiles - Major Brands
7.3.1 Metformin
7.3.2 Sulfonylureas and Other Insulin Secretagogues
7.3.3 a-glucosidase Inhibitors
7.3.4 Thiazolidinediones
7.3.5 Glucagon-Like Peptide-1 Receptor Agonists
7.3.6 Dipeptidyl-Peptidase 4 Inhibitors
7.3.7 Sodium-Glucose Cotransporter 2 Inhibitors
7.3.8 Insulin Formulations

8 Unmet Needs and Opportunities
8.1 Overview
8.2 Disease-Modifying Treatments Providing Sustained Glycemic Control
8.2.1 Unmet Need
8.2.2 Gap Analysis
8.2.3 Opportunity
8.3 Drugs with Non-Glycemic Benefits
8.3.1 Unmet Need
8.3.2 Gap Analysis
8.3.3 Opportunity
8.4 Drugs with Improved Side-Effect Profiles
8.4.1 Unmet Need
8.4.2 Gap Analysis
8.4.3 Opportunity
8.5 Increased Patient Compliance
8.5.1 Unmet Need
8.5.2 Gap Analysis
8.5.3 Opportunity

9 Pipeline Assessment
9.1 Overview
9.2 Clinical Trial Mapping
9.2.1 Clinical Trials by Country
9.2.2 Clinical Trials by Phase and Trial Status
9.3 Promising Drugs in Clinical Development
9.3.1 Semaglutide
9.3.2 OG217SC/Semaglutide (oral)
9.3.3 ITCA 650
9.3.4 Ertugliflozin
9.3.5 Sotagliflozin
9.3.6 Bexagliflozin

10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Company Profiles
10.3.1 Eli Lilly
10.3.2 Novo Nordisk
10.3.3 Sanofi
10.3.4 AstraZeneca
10.3.5 Merck & Co.
10.3.6 Boehringer Ingelheim
10.3.7 GlaxoSmithKline
10.3.8 Takeda
10.3.9 Roche
10.3.10 Pfizer
10.3.11 Johnson & Johnson
10.3.12 Novartis
10.3.13 Intarcia Therapeutics
10.3.14 Theracos

11 Market Outlook
11.1 Global Markets
11.1.1 Forecast
11.1.2 Drivers and Barriers - Global Issues
11.2 US
11.2.1 Forecast
11.2.2 Key Events
11.2.3 Drivers and Barriers
11.3 France
11.3.1 Forecast
11.3.2 Key Events
11.3.3 Drivers and Barriers
11.4 Germany
11.4.1 Forecast
11.4.2 Key Events
11.4.3 Drivers and Barriers
11.5 Italy
11.5.1 Forecast
11.5.2 Key Events
11.5.3 Drivers and Barriers
11.6 Spain
11.6.1 Forecast
11.6.2 Key Events
11.6.3 Drivers and Barriers
11.7 UK
11.7.1 Forecast
11.7.2 Key Events
11.7.3 Drivers and Barriers
11.8 Japan
11.8.1 Forecast
11.8.2 Key Events
11.8.3 Drivers and Barriers

12 Appendix
12.1 Bibliography
12.2 Abbreviations
12.3 Methodology
12.4 Forecasting Methodology
12.4.1 Diagnosed T2D Patients
12.4.2 Percent Drug-Treated Patients
12.4.3 Drugs Included in Each Therapeutic Class
12.4.4 Launch and Patent Expiry Dates
12.4.5 General Pricing Assumptions
12.4.6 Individual Drug Assumptions
12.4.7 Generic Erosion
12.4.8 Pricing of Pipeline Agents
12.5 Physicians and Specialists Included in this Study
12.6 About the Authors
12.6.1 Managing Analyst
12.6.2 Therapy Area Director
12.6.3 Epidemiologists
12.6.4 Global Director of Therapy Analysis and Epidemiology
12.6.5 Global Head and EVP of Healthcare Operations and Strategy
12.7 About
12.8 Contact
12.9 Disclaimer

List of Tables
Table 1: T2D: Key Metrics in the Seven Major Pharmaceutical Markets
Table 2: Overall Unmet Needs - Current Level of Attainment
Table 3: Primary pathophysiologic conditions associated with T2D
Table 4: Symptoms of T2D
Table 5: Risk Factors and Comorbidities for T2D.
Table 6: 7MM, Diagnosed Prevalent Cases of T2D, Ages =20 Years, Both Sexes, N, Selected Years 2016-2026
Table 7: Diagnostic Tests and Typical Criteria for Diagnosing T2D
Table 8: T2D Treatments
Table 9: Country Profile, T2D Management, US
Table 10: Country Profile, T2D Management, France
Table 11: Country Profile, T2D Management, Germany
Table 12: Country Profile, T2D Management, Italy
Table 13: Country Profile, T2D Management, Spain
Table 14: Country Profile, T2D Management, UK
Table 15: Country Profile, T2D Management, Japan
Table 16: Leading Branded Treatments for T2D, 2016
Table 17: Product Profile - Metformin
Table 18: Metformin SWOT Analysis, 2016
Table 19: First-Generation SUs
Table 20: Second-Generation SUs
Table 21: : Product Profile - SUsTable 26
Table 22: SUs SWOT Analysis, 2016
Table 23: Product Profile - Acarbose
Table 24: AGIs SWOT Analysis, 2016
Table 25: Product Profile - Actos
Table 26: TZDs SWOT Analysis, 2016
Table 27: GLP-1RAs
Table 28: Product Profile - Byetta
Table 29: Byetta SWOT Analysis, 2016
Table 30: Product Profile - Victoza
Table 31: Victoza SWOT Analysis, 2016
Table 32: Product Profile - Bydureon
Table 33: Bydureon SWOT Analysis, 2016
Table 34: Product Profile - Lyxumia
Table 35: Lyxumia SWOT Analysis, 2016
Table 36: Product Profile - Tanzeum
Table 37: Tanzeum SWOT Analysis, 2016
Table 38: Product Profile - Trulicity
Table 39: Trulicity SWOT Analysis, 2016
Table 40: Marketed DPP-4Is
Table 41: Marketed DPP-4Is in Combination with Other OADs
Table 42: Product Profile - Januvia
Table 43: Januvia SWOT Analysis, 2016
Table 44: Product Profile - Onglyza
Table 45: Onglyza SWOT Analysis, 2016
Table 46: Product Profile - Tradjenta
Table 47: Tradjenta SWOT Analysis, 2016
Table 48: Product Profile - Galvus
Table 49: Galvus SWOT Analysis, 2016
Table 50: Product Profile - Nesina
Table 51: Nesina SWOT Analysis, 2016
Table 52: Product Profile - Tenelia
Table 53: Tenelia SWOT Analysis, 2016
Table 54: Product Profile - Suiny
Table 55: Suiny SWOT Analysis, 2016
Table 56: Product Profile - Zafatek
Table 57: Zafatek SWOT Analysis, 2016
Table 58: Product Profile - Marizev
Table 59: Marizev SWOT Analysis, 2016
Table 60: SGLT-2Is
Table 61: Marketed SGLT-2Is in Combination with Other T2D Drugs
Table 62: Product Profile - Forxiga
Table 63: Forxiga SWOT Analysis, 2016
Table 64: Product Profile - Invokana
Table 65: Invokana SWOT Analysis, 2016
Table 66: Product Profile - Jardiance
Table 67: Jardiance SWOT Analysis, 2016
Table 68: Product Profile - Apleway
Table 69: Apleway SWOT Analysis, 2016
Table 70: Product Profile - Suglat
Table 71: Suglat SWOT Analysis, 2016
Table 72: Product Profile - Lusefi
Table 73: Lusefi SWOT Analysis, 2016
Table 74: Insulins - Overview and Comparison
Table 75: Marketed Combination Insulins
Table 76: Insulin Formulations
Table 77: Product Profile - Humalog
Table 78: Humalog SWOT Analysis, 2016
Table 79: Product Profile - Lantus
Table 80: Lantus SWOT Analysis, 2016
Table 81: Toujeo SWOT Analysis, 2016
Table 82: Product Profile - Levemir
Table 83: Levemir SWOT Analysis, 2016
Table 84: Product Profile - NovoLog
Table 85: NovoLog SWOT Analysis, 2016
Table 86: Fiasp SWOT Analysis, 2016
Table 87: Product Profile - Apidra
Table 88: Apidra SWOT Analysis, 2016
Table 89: Product Profile - Tresiba
Table 90: Tresiba SWOT Analysis, 2016
Table 91: Product Profile - Afrezza
Table 92: Afrezza SWOT Analysis, 2016
Table 93: Product Profile - Insulin glargine biosimilars
Table 94: Insulin Glargine Biosimilars SWOT Analysis, 2016
Table 95: Unmet Needs and Opportunities in T2D
Table 96: T2D - Clinical Trials by Phase and Status, 2016
Table 97: T2D - Phase Pipeline, 2016
Table 98: Comparison of Therapeutic Classes in Development for T2D, 2016
Table 99: Product Profile - Semaglutide
Table 100: Semaglutide SWOT Analysis, 2016
Table 101: Product Profile - OG217SC
Table 102: OG217SC SWOT Analysis, 2016
Table 103: Product Profile - ITCA 650
Table 104: ITCA 650 SWOT Analysis, 2016
Table 105: Product Profile - Ertugliflozin
Table 106: Ertugliflozin SWOT Analysis, 2016
Table 107: Product Profile - Sotagliflozin
Table 108: Sotagliflozin SWOT Analysis, 2016
Table 109: Product Profile - Bexagliflozin
Table 110: Bexagliflozin SWOT Analysis, 2016
Table 111: Key Companies in the T2D Market, 2016
Table 112: Other Companies in the T2D Market, 2016
Table 113: Eli Lilly’s T2D Portfolio Assessment, 2016
Table 114: Eli Lilly SWOT Analysis, 2016
Table 115: Novo Nordisk’s T2D Portfolio Assessment, 2016
Table 116: Novo Nordisk SWOT Analysis, 2016
Table 117: Sanofi’s T2D Portfolio Assessment, 2016
Table 118: Sanofi SWOT Analysis, 2016
Table 119: AstraZeneca’s T2D Portfolio Assessment, 2016
Table 120: AstraZeneca SWOT Analysis, 2016
Table 121: Merck’s T2D Portfolio Assessment, 2016
Table 122: Merck SWOT Analysis, 2016
Table 123: BI’s T2D Portfolio Assessment, 2016
Table 124: BI SWOT Analysis, 2016
Table 125: GSK’s T2D Portfolio Assessment, 2016
Table 126: GSK SWOT Analysis, 2016
Table 127: Takeda’s T2D Portfolio Assessment, 2016
Table 128: Takeda SWOT Analysis, 2016
Table 129: Roche’s T2D Portfolio Assessment, 2016
Table 130: Roche SWOT Analysis, 2016
Table 131: Pfizer’s T2D Portfolio Assessment, 2016
Table 132: Pfizer SWOT Analysis, 2016
Table 133: J&J’s T2D Portfolio Assessment, 2016
Table 134: J&J SWOT Analysis, 2016
Table 135: Novartis’ T2D Portfolio Assessment, 2016
Table 136: Novartis SWOT Analysis, 2016
Table 137: Intarcia Therapeutics’ T2D Portfolio Assessment, 2016
Table 138: Intarcia Therapeutics SWOT Analysis, 2016
Table 139: Theracos’ T2D Portfolio Assessment, 2016
Table 140: Theracos, SWOT Analysis, 2016
Table 141: T2D Market - Drivers and Barriers, 2016
Table 142: Key Events Impacting Sales for T2D in US, 2016-2026
Table 143: T2D Market - Drivers and Barriers in the US, 2016
Table 144: Key Events Impacting Sales for T2D in Germany, 2016-2026
Table 145: T2D Market - Drivers and Barriers in France, 2016
Table 146: Key Events Impacting Sales for T2D in Germany, 2016-2026
Table 147: T2D Market - Drivers and Barriers in Germany, 2016
Table 148: Key Events Impacting Sales for T2D in Italy, 2016-2026
Table 149: T2D Market - Drivers and Barriers in Italy, 2016
Table 150: Key Events Impacting Sales for T2D in Spain, 2016-2026
Table 151: T2D Market - Drivers and Barriers in Spain, 2016
Table 152: Key Events Impacting Sales for T2D in the UK, 2016-2026
Table 153: T2D Market - Drivers and Barriers in the UK, 2016
Table 154: Key Events Impacting Sales for T2D in Japan, 2016-2026
Table 155: T2D Market - Drivers and Barriers in Japan, 2016
Table 156: Key Launch Dates
Table 157: Key Patent Expiries
Table 158: Number of High-Prescribing Physicians Surveyed

List of Figures
Figure 1: Global Sales for T2D by Country/Region, 2016 and 2026
Figure 2: Company Portfolio Gap Analysis in T2D, 2016-2026
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in T2D, 2016-2026
Figure 4: T2D Pathophysiology
Figure 5: 7MM, Age-Standardized Diagnosed Prevalence (%) of T2D , Men, Ages =20 Years, 2006-2026
Figure 6: 7MM, Age-Standardized Diagnosed Prevalence (%) of T2D , Women, Ages =20 Years, 2006-2026
Figure 7: 7MM, Sources Used and Not Used, Diagnosed Prevalent Cases of T2D
Figure 8: 7MM, Sources Used, Prevalent Cases of CKD Among the Diagnosed Prevalent Cases of T2D
Figure 9: 7MM, Sources Used, Prevalent Cases of CVD Among the Diagnosed Prevalent Cases of T2D
Figure 10: 7MM, Sources Used, Prevalent Cases of Obesity Among the Diagnosed Prevalent Cases of T2D
Figure 11: 7MM, Sources Used, Prevalent Cases of Hypertension Among the Diagnosed Prevalent Cases of T2D
Figure 12: 7MM, Sources Used, Prevalent Cases of Dyslipidemia Among the Diagnosed Prevalent Cases of T2D
Figure 13: 7MM, Age-Specific Diagnosed Prevalent Cases of T2D, Ages =20 Years, Both Sexes, N, 2016
Figure 14: 7MM, Sex-Specific Diagnosed Prevalent Cases of T2D, Ages =20 Years, N, 2016
Figure 15: 7MM, Prevalent Cases of CKD Among the Diagnosed Prevalent Cases of T2D, Ages =20 Years, Both Sexes, N, 2016
Figure 16: 7MM, Prevalent Cases of CVD Among the Diagnosed Prevalent Cases of T2D, Ages =20 Years, Both Sexes, N, 2016
Figure 17: 7MM, Prevalent Cases of Obesity Among the Diagnosed Prevalent Cases of T2D, Ages =20 Years, Both Sexes, N, 2016
Figure 18: 7MM, Prevalent Cases of Hypertension Among the Diagnosed Prevalent Cases of T2D, Ages =20 Years, Both Sexes, N, 2016
Figure 19: 7MM, Prevalent Cases of Dyslipidemia Among the Diagnosed Prevalent Cases of T2D, Ages =20 Years, Both Sexes, N, 2016
Figure 20: Incretin and SGLT-2I Mechanisms of Action
Figure 21: ADA/EASD General Recommendations for Antihyperglycemic Therapy
Figure 22: Pipeline Agents in Develpoment for T2D
Figure 23: Competitive Assessment of Late-Stage Pipeline Agents in T2D, 2016-2026
Figure 24: Company Portfolio Gap Analysis in T2D, 2016-2026
Figure 25: Global Sales for T2D by Country/Region, 2016 and 2026
Figure 26: Sales for T2D in the US by Drug Class, 2016 and 2026
Figure 27: Sales for T2D in the France by Drug Class, 2016 and 2026
Figure 28: Sales for T2D in the Germany by Drug Class, 2016 and 2026
Figure 29: Sales for T2D in the Italy by Drug Class, 2016 and 2026
Figure 30: Sales for T2D in the Spain by Drug Class, 2016 and 2026
Figure 31: Sales for T2D in the UK by Drug Class, 2016 and 2026
Figure 32: Sales for T2D in the Japan by Drug Class, 2016 and 2026
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Eli Lilly
  • Novo Nordisk
  • Sanofi
  • AstraZeneca
  • Merck & Co.
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Takeda
  • Roche
  • Pfizer
  • Johnson & Johnson
  • Novartis
  • Intarcia Therapeutics
  • Theracos
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll